MedTrace Logo

Aurograb and Vancomycin in MRSA Infection

NCT00217841 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2006-09-19

No results posted yet for this study

Summary

The study hypothesis is that the addition of Aurograb to standard vancomycin therapy will improve outcome in MRSA infection.

Conditions

  • Staphylococcal Infections

Interventions

DRUG

Aurograb

Sponsors & Collaborators

  • NeuTec Pharma

    lead INDUSTRY

Principal Investigators

  • Mark H Wilcox, MD · Leeds Teaching Hospitals NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
ECT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2006-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00217841 on ClinicalTrials.gov